The biotherapeutics market is evolving, and emerging companies are advancing cutting-edge therapies to keep pace with innovation. The potential for life-changing, curative solutions where limited options exist makes this an exciting time to be in biotech. Although patient focus is constant, regulatory concerns and investment capital needs evolve as biopharma startups move their products from development to approval.
This article addresses how early-stage biotherapeutic companies can avoid common pitfalls and access support as they navigate the funding and regulatory processes to bring novel therapeutics from research to market. The thought leaders participating in this forum are working to develop viral vectors, cell and gene therapies, and bioengineered vaccines.
Frost & Sullivan recently invited industry leaders with experience working with drug development regulatory challenges to participate in a thought leadership forum. This forum brought together leading minds in this dynamic field to discuss regulatory challenges inherent in the development of therapeutics.